Puma Biotechnology, Inc.
PBYINASDAQHealthcare● Active
$6.85
$-0.18(-2.56%)
Market Cap$348661274
P/E Ratio—
52W High$7.9
52W Low$3.03
Puma Biotechnology, Inc. (PBYI) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PBYI · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.04
Est. -$0.13 · +69.2%
Revenue
$0.04B
Est. $0.04B · +6.7%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 9-Quarter EPS Beat Streak
PBYI reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.12
Rev. $4.47B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.12
Rev. Est.$4.47B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | $0.07 | — | — | — | $0.05B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.13 | -$0.04 | +69.2% | $0.04B | $0.04B | +6.7% |
| ▲ Q1 FY2026 | Feb 26, 2026 | $0.24 | $0.29 | +20.8% | $0.06B | $0.07B | -12.7% |
| ▲ Q4 FY2025 | Nov 6, 2025 | $0.09 | $0.21 | +133.3% | $0.05B | $0.07B | -20.6% |
| ▲ Q3 FY2025 | Aug 7, 2025 | $0.11 | $0.15 | +36.4% | $0.05B | $0.05B | +2.8% |
| ▲ Q2 FY2025 | May 8, 2025 | $0.02 | $0.10 | +400.0% | $0.05B | $0.05B | -12.8% |
| ▲ Q1 FY2025 | Feb 27, 2025 | $0.10 | $0.43 | +330.0% | $0.06B | $0.05B | +12.5% |
| ▲ Q4 FY2024 | Nov 7, 2024 | $0.35 | $0.41 | +17.1% | $0.08B | $0.05B | +53.4% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
$0.07
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.04
EPS Est.
-$0.13
EPS Surpr.
+69.2%
Revenue
$0.04B
Q1 FY2026
Feb 26, 2026Beat
EPS Actual
$0.29
EPS Est.
$0.24
EPS Surpr.
+20.8%
Revenue
$0.06B
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
$0.21
EPS Est.
$0.09
EPS Surpr.
+133.3%
Revenue
$0.05B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
$0.15
EPS Est.
$0.11
EPS Surpr.
+36.4%
Revenue
$0.05B
Q2 FY2025
May 8, 2025Beat
EPS Actual
$0.10
EPS Est.
$0.02
EPS Surpr.
+400.0%
Revenue
$0.05B
Q1 FY2025
Feb 27, 2025Beat
EPS Actual
$0.43
EPS Est.
$0.10
EPS Surpr.
+330.0%
Revenue
$0.06B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
$0.41
EPS Est.
$0.35
EPS Surpr.
+17.1%
Revenue
$0.08B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.18 | $0.18 | $0.18 | 1 |
| Q3 FY2026 | $0.10 | $0.15 | $0.20 | 1 |
| Q2 FY2026 | $0.04 | $0.04 | $0.04 | 1 |
| Q1 FY2026 | $-0.17 | $-0.17 | $-0.16 | 1 |
| Q4 FY2025 | $0.18 | $0.19 | $0.20 | 1 |
| Q3 FY2025 | $0.04 | $0.04 | $0.04 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2026 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2026 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2025 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2025 | $0.1B | $0.1B | $0.1B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +69.2% | $7.45 | $7.26 | -2.55% |
| ▲ Q1 FY2026 | Feb 26, 2026 | +20.8% | $7.68 | $7.60 | -1.04% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +133.3% | $4.95 | $4.90 | -1.01% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +36.4% | $3.25 | $3.29 | +1.23% |
| ▲ Q2 FY2025 | May 8, 2025 | +400.0% | $2.99 | $3.07 | +2.68% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +330.0% | $2.77 | $2.99 | +7.94% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +17.1% | $3.06 | $3.03 | -0.98% |
| ▲ Q3 FY2024 | Aug 1, 2024 | +50.0% | $3.59 | $3.50 | -2.51% |
Q2 FY2026-2.55%
Report Date
May 7, 2026
EPS Beat/Miss
+69.2%
Price Before
$7.45
Price After
$7.26
Q1 FY2026-1.04%
Report Date
Feb 26, 2026
EPS Beat/Miss
+20.8%
Price Before
$7.68
Price After
$7.60
Q4 FY2025-1.01%
Report Date
Nov 6, 2025
EPS Beat/Miss
+133.3%
Price Before
$4.95
Price After
$4.90
Q3 FY2025+1.23%
Report Date
Aug 7, 2025
EPS Beat/Miss
+36.4%
Price Before
$3.25
Price After
$3.29
Q2 FY2025+2.68%
Report Date
May 8, 2025
EPS Beat/Miss
+400.0%
Price Before
$2.99
Price After
$3.07
Q1 FY2025+7.94%
Report Date
Feb 27, 2025
EPS Beat/Miss
+330.0%
Price Before
$2.77
Price After
$2.99
Q4 FY2024-0.98%
Report Date
Nov 7, 2024
EPS Beat/Miss
+17.1%
Price Before
$3.06
Price After
$3.03
Q3 FY2024-2.51%
Report Date
Aug 1, 2024
EPS Beat/Miss
+50.0%
Price Before
$3.59
Price After
$3.50
Avg Beat Reaction+0.47%
Beat Rate8 / 8 quarters
Largest Move+7.94% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PBYI ends December
Puma Biotechnology, Inc. (PBYI) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.04 — beating the analyst consensus of $-0.13 by +69.2%. PBYI has beaten EPS estimates for 9 consecutive quarters. The next PBYI earnings date is expected around September 1, 2026.
Each quarter, investors track PBYI earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PBYI revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PBYI's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PBYI earnings · 5 questionsPuma Biotechnology, Inc.'s next earnings report is expected around September 1, 2026. PBYI typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PBYI historically reports after market close (AMC).
PBYI earnings datewhen is PBYI earningsPBYI next earnings datewhen does PBYI report earningsPBYI earnings calendar
▸ Source: FMP · Puma Biotechnology, Inc. SEC filings · US GAAP · Puma Biotechnology, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026